Exelixis Inc patents expiration
1. Cabometyx patents expiration
CABOMETYX's oppositions filed in EPO
Can you believe CABOMETYX received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7579473 | EXELIXIS INC | c-Met modulators and methods of use |
Aug, 2026
(2 years from now) | |
| US11091439 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US8877776 | EXELIXIS INC | (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8497284 | EXELIXIS INC | C-met modulators and method of use |
Sep, 2024
(4 months from now) | |
| US11098015 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US11091440 | EXELIXIS INC | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer |
Jan, 2030
(5 years from now) | |
| US10034873 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2031
(7 years from now) | |
| US10039757 | EXELIXIS INC | C-Met modulator pharmaceutical compositions |
Jul, 2031
(7 years from now) | |
| US11298349 | EXELIXIS INC | Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds |
Feb, 2032
(7 years from now) | |
| US9724342 | EXELIXIS INC | C-met modulator pharmaceutical compositions |
Jul, 2033
(9 years from now) | |
| US11141413 | EXELIXIS INC | Method of treating renal cell carcinoma using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate |
Apr, 2037
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-227) | Jan 14, 2026 |
| New Indication(I-854) | Jan 22, 2024 |
| Orphan Drug Exclusivity(ODE-375) | Sep 17, 2028 |
| New Indication(I-873) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 29, 2017 |
| New Indication(I-760) | Dec 19, 2020 |
| New Product(NP) | Apr 25, 2019 |
| New Indication(I-792) | Jan 14, 2022 |
Drugs and Companies using CABOZANTINIB S-MALATE ingredient
NCE-1 date: 29 November, 2016
Market Authorisation Date: 25 April, 2016
Treatment: Treatment of advanced renal cell carcinoma; Treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy; Treatment of patients with hepatocellular carcinoma (...
Dosage: TABLET;ORAL
How can I launch a generic of CABOMETYX before it's drug patent expiration?
More Information on Dosage
CABOMETYX family patents
